Business Wire

MITSUBISHI-POWER

1.9.2020 03:02:04 CEST | Business Wire | Press release

Share
Mitsubishi Power Established With Renewed Commitment to Transforming Energy Systems Around the World

Mitsubishi Power, a major subsidiary of the Mitsubishi Heavy Industries (MHI) Group, officially changed its corporate name from Mitsubishi Hitachi Power Systems today. The rebrand marks the start of an exciting new chapter in the company’s mission to solve the foremost energy challenges of our time, including decarbonizing energy and bringing reliable power to people all over the world. With its new brand identity, which was developed after consultation with key customers, employees and partners, Mitsubishi Power moves forward in its ambition to become a leading energy solutions company with a broad spectrum of businesses in grid-level power generation, renewables, energy storage and digital technologies.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200831005285/en/

Following the rebrand, Mitsubishi Power becomes a wholly owned subsidiary of MHI Group. Its enhanced position within the Group will enable it to establish greater synergies with its sister companies and expand its business by tapping new customer categories. Mitsubishi Power will capitalize on existing investments in emerging energy solutions, such as hydrogen, ammonia and solar power, to address the diverse and increasingly complex energy needs of customers around the world.

Mr. Ken Kawai, President and CEO of Mitsubishi Power, Ltd., said, “Providing people access to clean, stable, and affordable power is among global society’s most urgent mandates today. With our new identity, Mitsubishi Power is exceptionally poised to lead in solving these challenges. Building on a legacy of strong engineering and distinctive service, we will develop even more cutting-edge solutions to better serve our customers while broadening our portfolio. As an energy solutions company, we will partner more closely with governments, utilities, industry leaders and our fellow companies within the MHI Group to create a future that is good for people and the planet.”

In addition to the new name and logo, Mitsubishi Power also unveiled a new mission statement and announced that it will adopt the MHI Group tagline “Move the World Forward” (See Annex A).

Throughout its history, Mitsubishi Power has built a strong position as a trusted partner to power generation companies globally. As it enters this new phase, the company will apply its world-leading engineering prowess, drive for innovation and renowned customer service to deliver reliable energy, ultimately galvanizing the progress of nations, communities and individuals everywhere.

About Mitsubishi Power, Ltd.

Mitsubishi Power, Ltd. is a leading provider and innovator of technology and solutions for the global energy sector. Headquartered in Yokohama, Japan, it is a wholly owned subsidiary of Mitsubishi Heavy Industries, Ltd., whose engineering and manufacturing businesses span energy, infrastructure, transport, aerospace and defense. With more than 18,000 employees across 31 countries worldwide, Mitsubishi Power designs, manufactures and maintains equipment and systems that drive decarbonization and ensure delivery of reliable power around the world. Among its solutions are a wide range of gas turbines including hydrogen-fueled gas turbines, solid-oxide fuel cells (SOFCs), and air quality control systems (AQCS). Committed to providing exemplary service and working with customers to imagine the future of energy, Mitsubishi Power is also spearheading the development of the digital power plant through its suite of AI-enabled TOMONITM solutions.

For more information, please visit https://power.mhi.com .

ANNEX A: Mitsubishi Power Corporate Identity

Brand Logo and Name

The new brand logo combines the three diamonds figurative mark of Mitsubishi with the English company name. The logo font, a roundish, modern design in a gothic typeface, was adopted to present an image of the advanced, environment-friendly power generation technologies that Mitsubishi Power seeks to offer, while at the same time expresses a corporate stance of responding flexibly to societal changes.

Mission Statement

Mitsubishi Power is creating a future that works for people and the planet by developing innovative power generation technology and solutions to enable the decarbonization of energy and deliver reliable power everywhere.

Tagline

“Move the World Forward”

ANNEX B: Mitsubishi Power Corporate Information

Representative

Ken Kawai, President and CEO

Global Headquarters

3-1, Minato Mirai 3-chome, Nishi-ku, Yokohama, Kanagawa, Japan

Regional Headquarters

Asia Pacific: Singapore

Greater China: Shanghai

Europe, Middle East and Africa: London

Americas: Lake Mary, Florida

Number of Employees Globally

18,356 (as of April 2020)

Number of Main

Group Companies

69 companies (including 8 companies in Japan)

Major Offerings

Power plants:

  • Gas turbine combined cycle (GTCC)
  • Steam power
  • Integrated coal gasification combined cycle (IGCC)
  • Geothermal

Products, equipment and services:

  • Gas turbines
  • Steam turbines
  • Boilers
  • Air quality control systems (AQCS)
  • Generators
  • Fuel cells
  • Control systems
  • Energy storage systems
  • Operation and maintenance (O&M)
  • Long term service agreements
  • Remote monitoring
  • Training

Link:

ClickThru

Social Media:

https://www.facebook.com/MitsubishiPowerGlobal

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye